SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-016343
Filing Date
2024-12-18
Accepted
2024-12-18 07:30:14
Documents
19
Period of Report
2024-12-18
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crvs-20241218x8k.htm   iXBRL 8-K 112158
2 EX-99.1 crvs-20241218xex99d1.htm EX-99.1 102520
3 GRAPHIC crvs-20241218x8k006.jpg GRAPHIC 25861
4 GRAPHIC crvs-20241218x8k007.jpg GRAPHIC 27701
5 GRAPHIC crvs-20241218xex99d1001.jpg GRAPHIC 5572
6 GRAPHIC crvs-20241218xex99d1002.jpg GRAPHIC 42789
7 GRAPHIC crvs-20241218xex99d1003.jpg GRAPHIC 44849
  Complete submission text file 0001558370-24-016343.txt   610623

Data Files

Seq Description Document Type Size
8 EX-101.SCH crvs-20241218.xsd EX-101.SCH 3281
9 EX-101.LAB crvs-20241218_lab.xml EX-101.LAB 15267
10 EX-101.PRE crvs-20241218_pre.xml EX-101.PRE 9936
21 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20241218x8k_htm.xml XML 4738
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 241557605
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)